Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.820
+0.060 (2.17%)
Jan 17, 2025, 4:00 PM EST - Market closed
Akoya Biosciences Revenue
Akoya Biosciences had revenue of $18.81M in the quarter ending September 30, 2024, a decrease of -25.39%. This brings the company's revenue in the last twelve months to $86.82M, down -4.98% year-over-year. In the year 2023, Akoya Biosciences had annual revenue of $96.63M with 29.09% growth.
Revenue (ttm)
$86.82M
Revenue Growth
-4.98%
P/S Ratio
1.61
Revenue / Employee
$263,076
Employees
330
Market Cap
139.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 96.63M | 21.77M | 29.09% |
Dec 31, 2022 | 74.86M | 19.94M | 36.31% |
Dec 31, 2021 | 54.92M | 12.47M | 29.39% |
Dec 31, 2020 | 42.44M | 207.00K | 0.49% |
Dec 31, 2019 | 42.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
AKYA News
- 10 days ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 10 days ago - Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers - Business Wire
- 5 weeks ago - Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions - GlobeNewsWire
- 2 months ago - Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewsWire
- 3 months ago - Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - GlobeNewsWire
- 3 months ago - Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - GlobeNewsWire